Roche receives FDA clearance for additional Alzheimer’s

Roche receives FDA clearance for additional Alzheimer’s disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

Roche, a leading biotechnology company, has obtained clearance from the U.S. Food and Drug Administration (FDA) for other Alzheimer’s disease Cerebrospinal Fluid (CSF) assays. The newly cleared assays, known as Elecsys tTau/Abeta42 ratio, are crucial in enabling timely diagnosis and facilitating treatment decisions for Alzheimer’s disease. The Elecsys tTau/Abeta42 ratio is designed to assist clinicians…

Biogen and Eisai's Alzheimer's Drug, Leqembi

FDA Advisory Committee Supports Biogen and Eisai’s Alzheimer’s Drug, Leqembi

Introduction: In a significant development, a committee of expert advisors to the U.S. Food and Drug Administrator has endorsed for full approval of an Alzheimer’s disease drug developed by Biogen Inc. in collaboration with Eisai. The committee’s unanimous 6-0 vote concluded that Leqembi, the drug in question, demonstrated clinical benefit for patients, meeting the prerequisite…

Neurodex Presents Breakthrough Research on Exosomes for Neurodegenerative Disease Diagnosis at 'Extracellular Vesicles: Friends and Foes II' Congress

NeuroDex Presents Breakthrough Research on Exosomes for Neurodegenerative Disease Diagnosis at ‘Extracellular Vesicles: Friends and Foes II’ Congress

Neurodegenerative diseases Neurodegenerative diseases are a complex and growing public health concern. These conditions, including Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia, can cause significant disability and reduced quality of life. Unfortunately, diagnosing these diseases can be challenging, with current diagnostic methods often requiring invasive procedures, such as brain imaging or lumbar puncture. Neurodex…